As per the Alzheimer’s Association, more than 5 million people in the United states are living with Alzheimer’s Disease, and by 2050, the prevalence is projected to propel to nearly 14 million people. Alzheimer’s is the 6th leading cause of death in the USA, it causes more deaths than Prostate and Breast cancer combined.
Women are at a higher risk of developing Alzheimer’s Disease. About two-thirds of the diagnosed AD patients are women.
Some of the key companies are working in the development of new therapeutic options that target specific genetic, molecular, and cellular mechanisms behind the disease in the Alzheimer’s Disease Market. The key players in AD market includes Neurotrope bioscience, Amarantus Bioscience Holdings, AgeneBio, Novartis, Cortexyme, TauRx Therapeutics, Otsuka Pharmaceutical, AC Immune, Genentech, Alkahest, AZ Therapies, Cerecin, vTv Therapeutics, and many others.
The Alzheimer’s Disease market size is anticipated to grow during the forecast period. Some of the key factors expected to drive the Alzheimer’s Disease market includes launch of upcoming therapies, better understanding and better awareness of diseases, increasing morbidity rate due to Alzheimer’s disease and increasing Research and Development in the domain that shall contribute to the development of novel therapeutics and many others.
For more detailed information visit: https://www.delveinsight.com/blog/alzheimers-disease-market/